Mirum Pharmaceuticals (MIRM) – Investment Analysts’ Weekly Ratings Updates

Mirum Pharmaceuticals (NASDAQ: MIRM) recently received a number of ratings updates from brokerages and research firms:

• 11/5/2026 – Mirum Pharmaceuticals had its price target lowered by Leerink Partners from $154.00 to $140.00. They now have an “outperform” rating on the stock.
• 11/4/2026 – Mirum Pharmaceuticals had its “strong-buy” rating reaffirmed by Raymond James Financial. They now have a $189.00 price target on the stock.
• 11/4/2026 – Mirum Pharmaceuticals had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $155.00 price target on the stock.
• 11/4/2026 – Mirum Pharmaceuticals had its price target raised by Citizens Jmp from $144.00 to $167.00. They now have a “market outperform” rating on the stock.
• 11/4/2026 – Mirum Pharmaceuticals had its price target raised by Cantor Fitzgerald from $155.00 to $160.00. They now have an “overweight” rating on the stock.
• 11/4/2026 – Mirum Pharmaceuticals had its price target raised by HC Wainwright from $200.00 to $202.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Mirum Pharmaceuticals was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
• 10/21/2026 – Mirum Pharmaceuticals had its price target raised by TD Cowen from $140.00 to $145.00. They now have a “buy” rating on the stock.
• 10/14/2026 – Mirum Pharmaceuticals had its price target raised by Stifel Nicolaus from $136.00 to $156.00. They now have a “buy” rating on the stock.
• 10/13/2026 – Mirum Pharmaceuticals had its “outperform” rating reaffirmed by Evercore. They now have a $146.00 price target on the stock.
• 10/12/2026 – Mirum Pharmaceuticals had its price target raised by Morgan Stanley from $137.00 to $152.00. They now have an “overweight” rating on the stock.
• 10/12/2026 – Mirum Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen.
• 10/12/2026 – Mirum Pharmaceuticals had its price target raised by Citigroup from $160.00 to $184.00. They now have a “buy” rating on the stock.
• 10/12/2026 – Mirum Pharmaceuticals had its price target raised by HC Wainwright from $195.00 to $200.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Mirum Pharmaceuticals had its price target raised by Royal Bank Of Canada from $135.00 to $155.00. They now have an “outperform” rating on the stock.
• 9/29/2026 – Mirum Pharmaceuticals had its price target raised by Robert W. Baird from $123.00 to $130.00. They now have an “outperform” rating on the stock.
• 9/28/2026 – Mirum Pharmaceuticals was given a new $144.00 price target by Morgan Stanley.
• 9/28/2026 – Mirum Pharmaceuticals had its “buy” rating reaffirmed by Citigroup. They now have a $160.00 price target on the stock, up from $145.00.
• 9/28/2026 – Mirum Pharmaceuticals had its price target raised by HC Wainwright from $140.00 to $195.00. They now have a “buy” rating on the stock.

Mirum Pharmaceuticals Stock Down 0.8%

Shares of MIRM stock traded down $0.75 on Monday, hitting $92.97. 327,319 shares of the stock were exchanged, compared to its average volume of 836,016. The company has a current ratio of 2.07, a quick ratio of 1.98 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $6.07 billion, a P/E ratio of -6.01 and a beta of 0.75. The business has a 50-day moving average of $89.29 and a 200 day moving average of $98.46. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $63.23 and a fifty-two week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative net margin of 134.75% and a negative return on equity of 97.25%. The firm had revenue of $185.72 million during the quarter, compared to analyst estimates of $178.07 million. During the same period in the prior year, the business posted $0.05 EPS. The firm’s quarterly revenue was up 39.6% compared to the same quarter last year. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.47 EPS for the current year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 6,001 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total value of $599,499.90. Following the sale, the chief financial officer directly owned 36,355 shares in the company, valued at approximately $3,631,864.50. The trade was a 14.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the sale, the senior vice president directly owned 1,274 shares in the company, valued at $127,400. This trade represents a 96.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 96,659 shares of company stock worth $9,425,700. 8.32% of the stock is owned by insiders.

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options.

Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.

Mirum serves patients in the United States and other markets, including parts of Europe.